Aileron Therapeutics (ALRN) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Aileron Therapeutics (NASDAQ:ALRN) issued its earnings results on Wednesday. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.08, reports.

Shares of ALRN traded up $0.08 during trading hours on Thursday, reaching $2.13. The stock had a trading volume of 74,600 shares, compared to its average volume of 56,683. Aileron Therapeutics has a 12 month low of $1.75 and a 12 month high of $12.96. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.10. The stock has a market cap of $29.92 million, a P/E ratio of -1.21 and a beta of 0.04.

In related news, major shareholder Bioventures Ltd Novartis sold 17,508 shares of the stock in a transaction on Friday, August 17th. The stock was sold at an average price of $2.10, for a total value of $36,766.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 51,046 shares of company stock worth $114,236. 16.10% of the stock is owned by company insiders.

A hedge fund recently raised its stake in Aileron Therapeutics stock. Millennium Management LLC increased its position in Aileron Therapeutics Inc (NASDAQ:ALRN) by 565.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 123,658 shares of the company’s stock after purchasing an additional 105,073 shares during the period. Millennium Management LLC owned approximately 0.84% of Aileron Therapeutics worth $670,000 at the end of the most recent quarter. Institutional investors own 6.05% of the company’s stock.

ALRN has been the topic of a number of recent research reports. ValuEngine upgraded Aileron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 11th. Zacks Investment Research cut Aileron Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 7th.

ILLEGAL ACTIVITY NOTICE: “Aileron Therapeutics (ALRN) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS” was published by WKRB News and is owned by of WKRB News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at

About Aileron Therapeutics

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Recommended Story: How does inflation affect different investments?

Earnings History for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply